66 completed, 14 terminated, 7 withdrawn, 2 active not recruiting. 45 Phase 2, 37 Phase 1, 14 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Recurrent Non-Small Cell Lung Cancer: new trials by email Literature Review of Recurrent Non-Small Cell Lung Cancer trials Research Report on Recurrent Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer ONO-7475, Osimertinib Mesylate - Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 78 | 2021-08-06 | 2026-03-13 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Nivolumab, Relatlimab, Carboplatin - Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 468 | 2021-02-17 | 2026-06-18 |
| Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab MV-NIS, Atezolizumab - Recurrent Non-Small Cell Lung Cancer | Phase 1 | Terminated | Vyriad, Inc. | 2 | 2017-08-03 | 2023-07-21 |
| Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer Cetuximab, NK immunotherapy - Recurrent Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer vitamin C, Modulated Electro-Hyperthermia (mEHT), Supportive care - Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Clifford Hospital, Guangzhou, China | 97 | 2015-12-01 | 2018-11-30 |
| Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery hypofractionated radiation therapy, cisplatin, etoposide - Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 21 | 2015-06-08 | 2025-06-12 |
| Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer cytology specimen collection procedure, therapeutic procedure, targeted therapy - Malignant Pericardial Effusion, Malignant Pleural Effusion | Not applicable | Terminated | Fox Chase Cancer Center | 1 | 2015-03-01 | 2019-09-04 |
| Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers Palliative Therapy, quality-of-life assessment, questionnaire administration - Caregiver, Psychological Impact of Cancer and Its Treatment | Not applicable | Completed | City of Hope Medical Center | 361 | 2015-02-05 | 2026-10-02 |
| Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer | Not applicable | Withdrawn | University of Southern California | 2014-10-01 | 2015-09-16 | |
| Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer cytology specimen collection procedure, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Not applicable | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 619 | 2014-08-01 | 2026-07-29 |
| Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer soy isoflavones, cisplatin, etoposide - Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 11 | 2014-08-01 | 2020-11-23 |
| S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib crizotinib, pemetrexed disodium, laboratory biomarker analysis - Adenocarcinoma of the Lung, Large Cell Lung Cancer | Phase 2 | Terminated | SWOG Cancer Research Network | 1 | 2014-08-01 | 2020-02-20 |
| Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer diffusion-weighted magnetic resonance imaging, 4-dimensional computed tomography, fludeoxyglucose F 18 - Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer | Not applicable | Withdrawn | Virginia Commonwealth University | 2014-07-01 | 2016-12-16 | |
| Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer docetaxel, pemetrexed disodium, gemcitabine hydrochloride - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Not applicable | Terminated | Barbara Ann Karmanos Cancer Institute | 4 | 2014-06-01 | 2020-09-24 |
| Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib pemetrexed disodium, carboplatin, cisplatin - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2014-06-01 | 2015-07-13 | |
| Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 13 | 2014-01-31 | 2020-09-03 |
| Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens nintedanib - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 6 | 2014-01-30 | 2017-06-08 |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer docetaxel, AZD4547 - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 2 | 2014-01-15 | 2023-06-29 |
| Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients exercise intervention, standard follow-up care, quality-of-life assessment - Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease | Not applicable | Completed | University of Wisconsin, Madison | 21 | 2013-12-01 | 2019-11-18 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
Showing 20 of 90. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (90) · Adenocarcinoma of Lung (12) · Carcinoma, Ovarian Epithelial (10) · Breast Neoplasms (8) · Colonic Neoplasms (8) · Rectal Neoplasms (8) · Salivary Gland Neoplasms (8) · Small Cell Lung Carcinoma (8) · Squamous Cell Carcinoma of Head and Neck (8) · Pancreatic Neoplasms (7) · Adenocarcinoma, Bronchiolo-Alveolar (6) · Esthesioneuroblastoma, Olfactory (6) · Lung Neoplasms (6) · Stomach Neoplasms (6) · Anus Neoplasms (5)
Bronchial Neoplasms (90) · Carcinoma, Bronchogenic (90) · Lung Diseases (90) · Neoplasms by Site (90) · Respiratory Tract Diseases (90) · Respiratory Tract Neoplasms (90) · Thoracic Neoplasms (90) · Neoplasms (88) · Lung Neoplasms (84) · Neoplasms by Histologic Type (29) · Neoplasms, Glandular and Epithelial (29) · Carcinoma (28) · Adenocarcinoma (23) · Endocrine Gland Neoplasms (15) · Endocrine System Diseases (15)
Carboplatin (16) · Erlotinib Hydrochloride (15) · Paclitaxel (13) · Taxes (10) · Docetaxel (9) · Cisplatin (8) · Pemetrexed (8) · Bortezomib (7) · Cetuximab (6) · Gemcitabine (6) · Bevacizumab (5) · Sirolimus (4) · Celecoxib (3) · Etoposide (3) · Pharmacogenomic Testing (3)
National Cancer Institute (NCI) (45) · Barbara Ann Karmanos Cancer Institute (3) · City of Hope Medical Center (3) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · University of Washington (3) · Wake Forest University Health Sciences (3) · Jonsson Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · University of Southern California (2) · Vanderbilt-Ingram Cancer Center (2) · AIDS Malignancy Consortium (1) · Bristol-Myers Squibb (1) · Clifford Hospital, Guangzhou, China (1) · ECOG-ACRIN Cancer Research Group (1)
United States (80) · China (3) · Canada (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Mexico (1)
Alex Adjei (3) · Shirish Gadgeel (3) · Angela Davies (2) · Anne Traynor (2) · Charles Rudin (2) · David Camidge (2) · Karen Reckamp (2) · Leora Horn (2) · Miguel Villalona-Calero (2) · William Carson (2) · Agustin Garcia (1) · Alain Mita (1) · Alan Sandler (1) · Alice Bexon, MD (1) · Antonius Miller (1)
PMID 17167137, PMID 24100924, PMID 24246704, PMID 25965900, PMID 26062933, PMID 26611425, PMID 28598227, PMID 30497431, PMID 30850872, PMID 35429391, PMID 38206614
U10CA021115 (6), U10CA032102 (6), N01CM62209 (5), U01CA076576 (5), N01CM62201 (4), P30CA022453 (4), U10CA025224 (3), U10CA031946 (3), N01CM17101 (2), N01CM62208 (2), P30CA014520 (2), P30CA016672 (2), P30CA068485 (2), N01CM00032 (1), N01CM00039 (1)